Oxford BioMedica break-even still just out of reach
This article was originally published in Scrip
Executive Summary
Oxford BioMedica tried to reassure shareholders in its first-half results announcement that it has enough cash to last until the first quarter of 2013, and that trial results in the meantime could trigger milestone payments from partner Sanofi and deals on other key drugs. However, a number of positive developments are still needed before investors in the company, which carried out the UK's biggest public biotech fundraising this year in January (raising £20 million), will be able to breathe something of a sigh of relief.